Independent
Tenure on this board
10.4 yrs
Also a director at
Madrigal Pharmaceuticals Inc (MDGL)Cytokinetics Inc (CYTK)
3 nominees · 4 ballot items.
Election of three Class I directors; advisory approval of named executive officer compensation (say-on-pay); ratification of Ernst & Young LLP as independent registered public accounting firm; approval of an amendment to the 2024 Equity Incentive Plan to increase authorized shares by 5,209,670.
Elect three Class I director nominees (James M. Daly; Edmund P. Harrigan, M.D.; Adora Ndu, Pharm.D., J.D.) to hold office until 2029 Annual Meeting.
Non-binding advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the proxy statement.
This management proposal requests an advisory, non-binding approval of the Company’s executive compensation program as disclosed in the proxy statement. Management seeks affirmation from stockholders that the pay mix, performance metrics, and governance features described (including substantial at-risk compensation, use of PSUs tied to relative TSR and product sales, stock ownership guidelines, clawback policy and stock option practices) are appropriate. The board and Compensation Committee emphasize that the program is designed to align executive incentives with long-term stockholder value, retain key executives, and reward performance while incorporating governance safeguards (e.g., no option repricing without stockholder approval, clawback policy, minimum vesting periods and anti-hedging policies). The vote is non-binding but the board and Compensation Committee will consider the outcome in future compensation decisions. The context includes prior strong support for say-on-pay (98% in 2025) and a compensation program that remained largely market-aligned with peer companies; the board recommends a vote FOR, noting that compensation is primarily at-risk and tied to measurable goals and long-term equity vehicle mix. The board’s rationale is to gauge stockholder support for its approach and maintain alignment of incentives with company strategy and retention needs.
Ratify the Audit Committee’s selection of Ernst & Young LLP as independent registered public accounting firm for fiscal 2026.
Approve amendment to 2024 Plan to increase aggregate shares authorized for issuance by 5,209,670 shares, change full-value debit ratio to 1.59 and increase ISO limit.
Proposal 4 asks shareholders to approve an amendment to the company’s 2024 Equity Incentive Plan to increase the share reserve by 5,209,670 shares, adjust fungible share-counting (full-value awards now debit 1.59 shares each), and raise the ISO ceiling. Management frames the request as necessary to maintain competitive equity grants for recruiting and retention, noting historical burn rates, outstanding awards, and projected run-rate where the requested increase is expected to cover needs through the 2027 annual meeting. The proposal emphasizes governance protections (no repricing without approval, minimum 12‑month vesting with limited exceptions, no evergreen, limitations on dividends and change-in-control treatment, clawback policy, and caps on non-employee director awards). The plan’s mechanics (fungible counting, returning share rules, and limitations on reissuance of certain withheld shares) reduce the potential for liberal inflation of share usage. The board’s recommendation FOR is rooted in preserving the company’s ability to grant long-term incentives that align employee interests with stockholder value, while pointing to responsible share-management practices and various anti-dilution and governance features. The analytical trade-offs include dilution to existing shareholders versus the retention and motivation benefits of equity awards; the proposed fungible ratio increases the efficiency of share usage for stock options but debits more heavily for full-value awards, which is intended to limit dilution from RSUs/PSUs.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 25.05% | 42,896,690 | $955M |
| 2 | BlackRock, Inc. | 8.48% | 14,516,607 | $323M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.06% | 8,671,645 | $193M |
| 4 | STATE STREET CORP | 4.87% | 8,332,771 | $185M |
| 5 | RTW INVESTMENTS, LP | 4.17% | 7,144,524 | $159M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 3.31% | 5,661,400 | $126M |
| 7 | BlackRock, Inc. | 2.50% | 4,272,981 | $95M |
| 8 | FIRST TRUST ADVISORS LP | 1.95% | 3,343,868 | $74M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.76% | 3,021,932 | $67M |
| 10 | DIMENSIONAL FUND ADVISORS LP | 1.75% | 2,993,174 | $67M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.